title: [Experience in the use of doxazosin in patients with benign hyperplasia of the prostate].
abstract: Selective alpha-1-adrenoblockers are thought promising in current conservative treatment of benign prostatic hyperplasia (BPH). The trial of doxazosin (cardura)--a selective alpha-blocker--included 78 BPH patients with obstructive urination. All the patients received a single daily dose of doxazosin 4-8 mg (mean 5.7 mg). 60 patients on placebo served as control. The comparison of the effects observed in the study vs control group has demonstrated that doxazosin has a favourable effect on BPH: it improved quality of life, relieved obstructive symptoms, reduced amount of residual urine. There is objective urodynamic evidence on decreased infravesical obstruction.
authors.forename: N A
authors.initials: NA
authors.lastname: Lopatkin
authors.forename: O B
authors.initials: OB
authors.lastname: Loran
authors.forename: D Iu
authors.initials: DIu
authors.lastname: Pushkar'
authors.forename: T S
authors.initials: TS
authors.lastname: Perepanova
authors.forename: K P
authors.initials: KP
authors.lastname: Tevlin
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D017292:Doxazosin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D011788:Quality of Life; D014555:Urination Disorders / Q000188:drug therapy / Q000209:etiology
chemical_list: D000317:Adrenergic alpha-Antagonists; D017292:Doxazosin
vernacular_title: Oøyt primeneniia doksazozina u bol'nykh dobrokachestvennoĭ giperplazieĭ prostaty.